Reaching and influencing consumers in the prescription medicine market

Marketing Intelligence and Planning

Volumn 27, Issue 7, 2009, Pages 909-925

  Peters, Julia ^a   Nel, Deon ^b   Adam, Stewart ^b  

^a BOND UNIVERSITY   (Australia)

^b DEAKIN UNIVERSITY   (Australia)

Author keywords

Drugs; Marketing communications; Marketing strategy; Medical prescriptions; Pharmaceuticals industry

Indexed keywords

EID: 70350306281     PISSN: 02634503     EISSN: None     Source Type: Journal    
DOI: 10.1108/02634500911000225     Document Type: Article

References (28)

1. Barclay, L. (2004), "Vioxx withdrawal prompts reevaluation of COX-2 inhibitor safety", New England Journal of Medicine, available at: www.medscape.com/viewarticle/490979 (accessed 17 March 2008).
2. Barnett, A. (1998), "Are drug ads a cure-all?", Business Week, March 30, pp. 59-60.
3. Barry, P. (2000), "Stories in 2000", Media Watch, Australian Broadcasting Corporation, Sydney, 10 July.
4. FDA News (2004), "FDA issues public health advisory on Vioxx as its manufacturer voluntarily withdraws the product", available at: www.fda.gov/bbs/topics/news/2004/NEW01122.html (accessed 10 March 2008).
5. Fiorentino, P.M., Tallents, R.H., Miller, J.N., Brouxhon, S.M., O'Banion, M.K., Puzas, J.E. and Kyrkanides, S. (2008), "Spinal interleukin-1beta in a mouse model of arthritis and joint pain", Arthritis & Rheumatism, Vol. 58 No. 10, pp. 3100-9.
6. Gardner, D.M., Mintzes, B. and Ostry, A. (2003), "Direct-to-consumer prescription drug advertising in Canada: permission by default?", Canadian Medical Association Journal, Vol. 169 No. 5, pp. 1-6.
7. Gregory, S. (2009), "Are direct-to-consumer drug ads doomed?", Time, 4 February, available at: www.time.com/time/business/article/0,8599,1876679-1,00.html (accessed 11 March 2009).
8. Hall, D.V. and Jones, S.C. (2006), "Direct-to-consumer branding of prescription medicines in Australia", Proceedings of the Australian and New Zealand Marketing Academy (ANZMAC) Conference, Queensland University of Technology, Brisbane, 4-6 December.
9. Hassan-Alin, M., Naesdal, C., Nilsson-Pieschl, C., Langstrom, G. and Andersson, T. (2005), "Lack of pharmacokinetic interaction between esomeprazole and the nonsteroidal anti-inflammatory drugs naproxen and rofecoxib in healthy subjects", Clinical Drug Investigation, Vol. 25 No. 11, pp. 731-40.
10. Hoek, J. and Gendall, P. (2004), "Direct-to-consumer advertising of prescription medicines in the United States and New Zealand: an analysis of regulatory approaches and consumer responses", International Journal of Advertising, Vol. 23, pp. 197-227.
11. Hollon, M.F. (1999), "Direct-to-consumer marketing of prescription drugs: creating consumer demand", The Journal of the American Medical Association, Vol. 281, pp. 382-4.
12. Langreth, R. and Herper, M. (2006), "How the drug industry abandoned science for salesmanship", available at: www.forbes.com/forbes/2006/0508/094a.html (accessed 12 March 2009).
13. Lawrence, R.C., Helmick, C.G., Arnett, F.C., Deyo, R.A., Felson, D.T., Giannini, E.H., Heyse, S.P., Hirsch, R., Hochberg, M.C., Hunder, G.G., Liang, M.H., Pillemer, S.R., Steen, V.D. and Wolfe, F. (1998), "Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States", Arthritis & Rheumatism, Vol. 41 No. 5, pp. 778-99.
14. Merck Annual Report (2004), available at: www.merck.com/finance/annualreport/ar2004/home/ (accessed 15 March 2008).
15. Merck Sharp & Dohme (2008), available at: www.msd.com (accessed 22 March 2008).
16. Monsanto Annual Report (1999), available at: www.prnewswire.com/ (accessed 15 March 2008).
17. Morris, L. and Griffen, J. (1992), "The evolving role of FDA in prescription drug promotion", Journal of Drug Issues, Vol. 22 No. 2, pp. 245-56.
18. Peterson, I.F. (1996), "Occurrence of osteoarthritis of the peripheral joints in European populations", Annals of the Rheumatic Diseases, Vol. 55 No. 9, pp. 659-61.
19. Pfizer (2008), available at: www.pfizer.com/about/ (accessed 8 March 2008).
20. Pitt, L.F. and Nel, D. (1988), "Pharmaceutical promotion tools - their relative importance", European Journal of Marketing, Vol. 22 No. 5, pp. 7-14.
21. Porter, R. (2002), "New Cox-2 pain relievers are marketing marvel, not miracle drugs", available at: www.thefreelibrary.com/New+Cox-2+pain+relievers+are+marketing+marvel,+not+miracle+drugs-a093463470 (accessed 17 March 2008).
22. Smith, M.C. (2006), "The legislative environment of pharmaceutical marketing", Journal of Pharmaceutical Marketing & Management, Vol. 18 No. 1, pp. 17-89.
23. Spiegel, B. and Gralnek, I. (2004), "Cost-effectiveness of cyclooxygenase-2 inhibitors in chronic arthritis", Annals of Internal Medicine, Vol. 140 No. 9, pp. 761-2.
24. Stanford University Medical Center (2005), "Vioxx went mostly to patients who didn't need it, Stanford researcher says", available at: www.sciencedaily.com/releases/2005/01/050123210312.htm (accessed 15 November 2008).
25. Symmons, D., Turner, G., Webb, R., Asten, P., Barnett, E., Lunt, M., Scott, D. and Silman, A. (2002), "The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century", Rheumatology, Vol. 41 No. 7, pp. 793-800.
26. Wong, D., Wang, M., Cheng, Y. and Fitzgerald, G.A. (2005), "Cardiovascular hazard and non-steroidal anti-inflammatory drugs", Current Opinion in Pharmacology, Vol. 5 No. 5, pp. 204-10.
27. Yelin, E., Murphy, L., Cisternas, M., Foreman, A., Pasta, D. and Helmick, C. (2007), "Medical care expenditures and earnings losses among persons with arthritis and other rheumatic conditions in 2003", Arthritis & Rheumatism, Vol. 56 No. 5, pp. 1397-407.
28. Consumer Affairs (2005), available at: www.consumeraffairs.com/news04/2005/celebrex_blockbox.html (accessed 20 March 2008).